Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Effect of exchange rate changes on cash, cash equivalents and restricted cash

Effect of exchange rate changes on cash, cash equivalents and restricted cash at other companies

Zymeworks logo
ZymeworksZYME
$98K+880%

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's effect of exchange rate changes on cash, cash equivalents and restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's effect of exchange rate changes on cash, cash equivalents and restricted cash?
BioCryst Pharmaceuticals (BCRX) reported effect of exchange rate changes on cash, cash equivalents and restricted cash of -$72K in Q1 2026.
How has BioCryst Pharmaceuticals's effect of exchange rate changes on cash, cash equivalents and restricted cash changed year-over-year?
BioCryst Pharmaceuticals's effect of exchange rate changes on cash, cash equivalents and restricted cash decreased by 116.0% year-over-year, from $451K to -$72K.
What is the long-term trend for BioCryst Pharmaceuticals's effect of exchange rate changes on cash, cash equivalents and restricted cash?
Over 2 years (2022 to 2024), BioCryst Pharmaceuticals's effect of exchange rate changes on cash, cash equivalents and restricted cash has grown at a 27.0% compound annual growth rate (CAGR), from $580K to -$936K.
What does effect of exchange rate changes on cash, cash equivalents and restricted cash mean?
Measures the impact of fluctuations in foreign currency exchange rates on the reported value of cash and cash equivalents held in non-functional currencies. This provides insight into the company's exposure to currency volatility and the resulting impact on liquid asset balances.